Get the Stockscreener App
0.7163
4.73%
-0.0356
Invivyd Inc stock is traded at $0.7163, with a volume of 421.35K.
It is down -4.73% in the last 24 hours and up +0.18% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$0.7519
Open:
$0.75
24h Volume:
421.35K
Relative Volume:
0.25
Market Cap:
$85.93M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.3655
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
-11.57%
1M Performance:
+0.18%
6M Performance:
+100.25%
1Y Performance:
-42.70%
1-Day Range:
$0.7075
$0.7519
1-Week Range:
$0.7075
$0.8437
52-Week Range:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.7163 | 96.75M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.86 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.90 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
394.79 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.91 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.45 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
How does Invivyd Inc. compare to its industry peersAdvanced Screener Growth Plan For Every Investor - jammulinksnews.com
Invivyd Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingSwing Trading Plan With Smart Signals in Review - metal.it
What makes Invivyd Inc. stock price move sharplyOversold Bounce Stock Play Ideas Gain Attention - metal.it
How volatile is Invivyd Inc. stock compared to the marketLow Risk Watchlist With High Returns - jammulinksnews.com
Is Invivyd Inc. stock overvalued or undervaluedUnlock powerful trading tools for investors - jammulinksnews.com
Does Invivyd Inc. stock perform well during market downturnsMarket-crushing profits - jammulinksnews.com
How many analysts rate Invivyd Inc. as a “Buy”Navigate market shifts with confidence - jammulinksnews.com
What catalysts could drive Invivyd Inc. stock higher in 2025Daily Trading Opportunities For Consistent Profits - jammulinksnews.com
How does Invivyd Inc. generate profit in a changing economyBuild wealth with reliable stock picks - jammulinksnews.com
What institutional investors are buying Invivyd Inc. stockOutstanding risk-reward balance - jammulinksnews.com
What are the latest earnings results for Invivyd Inc.Find the best stocks for sustainable growth - jammulinksnews.com
Published on: 2025-07-27 18:51:12 - jammulinksnews.com
What are Invivyd Inc. company’s key revenue driversOutstanding capital growth - jammulinksnews.com
Why is Invivyd Inc. stock attracting strong analyst attentionCapitalize on fast-moving trading opportunities - jammulinksnews.com
How strong is Invivyd Inc. company’s balance sheetInvest in stocks with strong fundamentals - jammulinksnews.com
Is Invivyd Inc. a good long term investmentPhenomenal investment performance - PrintWeekIndia
What drives Invivyd Inc. stock priceHigh-octane financial growth - PrintWeekIndia
Invivyd Inc. Stock Analysis and ForecastDynamic growth stocks - PrintWeekIndia
What analysts say about Invivyd Inc. stockOutstanding yields - Autocar Professional
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome - The Manila Times
Yale immunobiologist Iwasaki joins Invivyd’s Long COVID research group - Investing.com
Yale immunobiologist Iwasaki joins Invivyd’s Long COVID research group By Investing.com - Investing.com South Africa
Invivyd, Inc.'s (NASDAQ:IVVD) Shift From Loss To Profit - simplywall.st
How Invivyd Inc. stock performs during market volatilityFree Stock Market Swing Trading Strategies - Newser
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MCGUIRE TERRANCE | Director |
Dec 27 '24 |
Sale |
0.52 |
83,744 |
43,647 |
3,256,776 |
| MCGUIRE TERRANCE | Director |
Dec 30 '24 |
Sale |
0.48 |
86,545 |
41,784 |
3,170,231 |
| MCGUIRE TERRANCE | Director |
Dec 20 '24 |
Sale |
0.42 |
119,805 |
50,725 |
3,568,274 |
| MCGUIRE TERRANCE | Director |
Dec 26 '24 |
Sale |
0.54 |
83,817 |
45,563 |
3,340,520 |
| MCGUIRE TERRANCE | Director |
Dec 24 '24 |
Sale |
0.51 |
68,161 |
34,503 |
3,424,337 |
| MCGUIRE TERRANCE | Director |
Dec 23 '24 |
Sale |
0.45 |
75,776 |
34,076 |
3,492,498 |
1.69%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):